TG Therapeutics CFO granted 90K restricted shares
TG Therapeutics CFO Sean A. Power reported an equity grant.
Rhea-AI Filing Summary
TG Therapeutics CFO Sean A. Power reported an equity grant. On 01/08/2026 he was awarded 90,000 shares of TG Therapeutics common stock at a price of $0 per share, reported as an acquisition of non-derivative securities.
These are restricted shares, with one quarter scheduled to vest on each of 01/01/2027, 01/01/2028, 01/01/2029, and 01/01/2030. After this grant, he beneficially owns 798,111 shares of common stock, including restricted shares that vest over various time periods, all held directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 90,000 | $0.00 | $0.00 |
Footnotes (2)
- F1. Reflects a grant of restricted shares, of which 1/4 will vest equally on 1/1/27, 1/1/28, 1/1/29, and 1/1/30.
- F2. Includes shares of restricted Common Stock, which vest over various time periods.
FAQ
What insider transaction did TG Therapeutics (TGTX) report for its CFO?
TG Therapeutics reported that CFO Sean A. Power acquired 90,000 shares of common stock on 01/08/2026 through a grant of restricted shares at a price of $0 per share.
Is the TG Therapeutics CFO transaction a purchase or a grant?
The transaction is coded "A" for acquisition and is described as a grant of restricted shares, rather than an open-market purchase.
Does this Form 4 for TG Therapeutics involve any derivative securities?
No derivative securities are reported in the provided tables; the transaction relates to non-derivative common stock in the form of restricted shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.